Antimalarial drugs in pregnancy - The North American experience

Lupus

Volumn 5, Issue SUPPL. 1, 1996, Pages

  Parke, A L ^a   Rothfield, N F ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

Antimalarial drugs; Chloroquine; Hydroxychloroquine (plaquenil); Pregnancy

Indexed keywords

ANTIMALARIAL AGENT; CHLOROQUINE; HYDROXYCHLOROQUINE;

ARTICLE; DRUG WITHDRAWAL; FEMALE; FETUS WASTAGE; HUMAN; NORTH AMERICA; PREGNANCY; PREGNANCY DISORDER; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 0029889796     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203396005001151     Document Type: Article

References (21)

1. Briggs GG, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation. Baltimore: Williams & Wilkins.
2. A Physician's Desk Reference, 1996, p. 2329.
3. Rudnicki RD, Gresham GE, Rothfield NF. The efficacy of antimalarials in systemic lupus erythematosus. J Rheumatol 1975; 2: 323-330.
4. The Canadian Hydroxychloroquine Study Group: A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl Med 1991; 324: 150-154.
5. Fraga A et al. Sterility and fertility rates, fetal wastage and maternal morbidity in systemic lupus erythematosus. J Rheumatol 1974; 1: 293-298.
6. Zurier RB et al. SLE management during pregnancy. Obstet Gynecology 1977; 51: 178-180.
7. Gimovsky HC, Monotoro M, Paul RH. Pregnancy outcome in women with systemic lupus erythematosus. Obstet Gynecology 1984; 63: 686-692.
8. Tett SE, Cutler DJ, Day RO, Brown KF. Bioavailability of hydroxychloroquine tablets in healthy volunteers. Br J Clin Pharmac 1989; 27: 771-779.
9. Henkind P, Rothfield NF. Ocular abnormalities in patients treated with synthetic antimalarial drugs. N Engl J Med 1963; 269: 433-439.
10. Hart CN, Naunton RF. The ototoxicity of chloroquine phosphate. Arch Otolaryngol Head Neck Surg 1964; 80: 407-412.
11. Paufique L, Magnard P. Degenerescence retinienne chez deux enfants consecutive a un traitement preventif antipaludeen chez la mere pendant la grossese. Bull Soc Ophthalmol Fr 1969; 59: 466-467.
12. Bernstein HN. Ocular safety of hydroxychloroquine. Ann Ophthalmol 1991; 23: 292-296.
13. Johnson MW, Vine AK. Hydroxychloroquine therapy in massive total doses without retinal toxicity. Am J Ophthalmol 1987; 104: 139-144.
14. Ullberg S, Lindquist NJ, Sjostrand SE. Accumulation of chorioretinotoxic drugs in the fetal eye. Nature 1970; 227: 1257-1258.
15. Wallace DJ. Antimalarial agents and lupus. Rheum Dis Clin N Amer 1994; 20: 243-263.
16. Parke AL. Antimalarial drugs, systemic lupus erythematosus and pregnancy. J Rheumatol 1988; 15: 607-610.
17. Parke A, West B. Antimalarial therapy in pregnancy. (in press).
18. Levy M et al. Pregnancy outcome following first trimester exposure to chloroquine. Am J Perinatal 1991; 8: 174-178.
19. Iredale J, Fieger H, Wainer IW. Determination of the stereoisomers of hydroxychloroquine and its major metabolites in plasma and urine following a single oral administration of racemic hydroxychloroquine. Sem Arthritis Rheum 1993; 23:74-81.
20. Ducharme J, Wainer JW, Parenteau HI, Rodman JH. Steroselective distribution of hydroxychloroquine in the rabbit following single and multiple oral doses of the racemate and the separate enantiomers. Chirality 1994; 6: 337-346.
21. Ducharme J et al. Enantioselective disposition of hydroxychloroquine after a single oral dose of the racemate to healthy subjects. Br J Clin Pharmacol 1995; 40: 127-133.